Pfizer's gene therapy for rare genetic bleeding disorder succeeds in late-stage trial
Post date: 2024-07-25 03:04:29
Views: 19
The hemophilia A treatment could become the company's second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.